The influence of polymorphisms of metabolic enzymes and transporters on pharmacokinetics and clinical response to imatinib, dasatinib and nilotinib

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RPC-16010078

Enrollment

Unknown

Registered

2016-12-04

Start date

2016-12-13

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia

Interventions

imatinib group:The determination of concentration and genotypes

dasatinib group:The determination of concentration and genotypes

nilotinib group:The determination of concentration and genotypes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with chronic myelogenous leukemia and taking imatinib, dasatinib or nilotinib regularly are included.

Exclusion criteria

Exclusion criteria: Patients allergic to imatinib, dasatinib or nilotinib; Patients stopping taking imatinib, dasatinib or nilotinib for any reasons are excluded.

Design outcomes

Primary

Measure	Time frame
plasma concentrations of imatinib, dasatinib or nilotinib;genotype;	—

Countries

China

Contacts

Public ContactXu Ping

The Second Xiangya Hospital of Central South University

xuping1109@163.com+86 13874882504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026